Cytokinetics Inc (CYTK) stock
CYTKNasdaqPharmaceutical PreparationsFiscal year ends December 31
$56.13−0.03 (-0.05%)
Close on Nov 13, 2026Market cap $7.80BP/E –Yield –
Cytokinetics profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Cytokinetics's profit margin for the twelve months ending Sep 30, 2026 was -686.6%. For fiscal 2025 it was -891.6%, against -3191.1% the year before. The highest annual figure on record is 30.1% in fiscal 2009.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -891.6% | +2299.5 |
| FY2024 | Dec 31, 2024 | -3191.1% | +3797.5 |
| FY2023 | Dec 31, 2023 | -6988.6% | −6577.4 |
| FY2022 | Dec 31, 2022 | -411.2% | −105.5 |
| FY2021 | Dec 31, 2021 | -305.7% | −77.7 |
| FY2020 | Dec 31, 2020 | -228.0% | +224.9 |
| FY2019 | Dec 31, 2019 | -452.9% | −115.5 |
| FY2018 | Dec 31, 2018 | -337.4% | +618.5 |
| FY2017 | Dec 31, 2017 | -955.9% | −971.4 |
| FY2016 | Dec 31, 2016 | 15.5% | +146.3 |
| FY2015 | Dec 31, 2015 | -130.9% | −99.7 |
| FY2014 | Dec 31, 2014 | -31.2% | +78.8 |
| FY2013 | Dec 31, 2013 | -110.0% | +424.1 |
| FY2012 | Dec 31, 2012 | -534.1% | +662.4 |
| FY2011 | Dec 31, 2011 | -1196.5% | +716.1 |
| FY2010 | Dec 31, 2010 | -1912.6% | −1942.7 |
| FY2009 | Dec 31, 2009 | 30.1% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -399.7% | +15415.3 |
| Q2 FY2026 | Jun 30, 2026 | -694.4% | −493.1 |
| Q1 FY2026 | Mar 31, 2026 | -1064.5% | +9155.7 |
| Q4 FY2025 | Dec 31, 2025 | -1030.9% | −144.6 |
| Q3 FY2025 | Sep 30, 2025 | -15815.0% | +18860.0 |
| Q2 FY2025 | Jun 30, 2025 | -201.2% | +57356.2 |
| Q1 FY2025 | Mar 31, 2025 | -10220.1% | +6024.5 |
| Q4 FY2024 | Dec 31, 2024 | -886.3% | +7301.3 |
| Q3 FY2024 | Sep 30, 2024 | -34674.9% | −436.3 |
| Q2 FY2024 | Jun 30, 2024 | -57557.4% | −42720.4 |
| Q1 FY2024 | Mar 31, 2024 | -16244.7% | −13398.6 |
| Q4 FY2023 | Dec 31, 2023 | -8187.6% | −1167.6 |
| Q3 FY2023 | Sep 30, 2023 | -34238.6% | −28580.2 |
| Q2 FY2023 | Jun 30, 2023 | -14837.0% | −14814.7 |
| Q1 FY2023 | Mar 31, 2023 | -2846.1% | +4945.3 |
| Q4 FY2022 | Dec 31, 2022 | -7019.9% | −6964.9 |
| Q3 FY2022 | Sep 30, 2022 | -5658.4% | −4259.0 |
| Q2 FY2022 | Jun 30, 2022 | -22.3% | +2142.8 |
| Q1 FY2022 | Mar 31, 2022 | -7791.4% | −7072.0 |
| Q4 FY2021 | Dec 31, 2021 | -55.0% | +598.5 |
| Q3 FY2021 | Sep 30, 2021 | -1399.4% | −1391.8 |
| Q2 FY2021 | Jun 30, 2021 | -2165.1% | −1030.1 |
| Q1 FY2021 | Mar 31, 2021 | -719.4% | +310.8 |
| Q4 FY2020 | Dec 31, 2020 | -653.5% | −65.7 |
| Q3 FY2020 | Sep 30, 2020 | -7.6% | +480.8 |
| Q2 FY2020 | Jun 30, 2020 | -1135.0% | −685.0 |
| Q1 FY2020 | Mar 31, 2020 | -1030.2% | −683.2 |
| Q4 FY2019 | Dec 31, 2019 | -587.9% | −305.6 |
| Q3 FY2019 | Sep 30, 2019 | -488.4% | −281.5 |
| Q2 FY2019 | Jun 30, 2019 | -450.0% | −7.1 |
| Q1 FY2019 | Mar 31, 2019 | -347.0% | +227.9 |
| Q4 FY2018 | Dec 31, 2018 | -282.3% | +241.3 |
| Q3 FY2018 | Sep 30, 2018 | -206.9% | +745.6 |
| Q2 FY2018 | Jun 30, 2018 | -442.8% | +180.0 |
| Q1 FY2018 | Mar 31, 2018 | -574.8% | −596.4 |
| Q3 FY2017 | Sep 30, 2017 | -523.6% | – |
| Q2 FY2017 | Jun 30, 2017 | -952.5% | – |
| Q1 FY2017 | Mar 31, 2017 | -622.9% | – |
| Q4 FY2016 | Dec 31, 2016 | 21.6% | – |
See a number that looks wrong?